Literature DB >> 17825343

Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody.

Per Johan Klasse1.   

Abstract

Trimers of the HIV-1 envelope glycoprotein (Env) effectuate viral entry into susceptible cells. Therefore Env trimers are the targets for neutralizing antibodies. This study models the number of trimers required for virion infectivity. It also delineates the minimum number of antibody molecules that would neutralize a virion. First, Env function was assumed to be incremental (all envelope glycoprotein units contribute equally) or liminal (characterized by thresholds). Then, such models were combined and shown to fit published data on phenotypically mixed pseudotype viruses. Virions with 9 trimers would require around a median of 5 of them for strong infectivity; the proportion varies among strains and mutants. In addition, the models account for both liminal and incremental protomeric effects at the trimer level: different inert Env mutants may affect trimer function in different degrees. Because of compensatory effects at the virion and trimer levels, however, current data cannot differentiate between all plausible models. But the biophysically and mathematically rationalized blurring of thresholds yields candidate models that fit different data excellently.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17825343      PMCID: PMC2317823          DOI: 10.1016/j.virol.2007.06.044

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  64 in total

1.  Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity.

Authors:  Eloísa Yuste; Jacqueline D Reeves; Robert W Doms; Ronald C Desrosiers
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

2.  The stoichiometry of Gag protein in HIV-1.

Authors:  John A G Briggs; Martha N Simon; Ingolf Gross; Hans-Georg Kräusslich; Stephen D Fuller; Volker M Vogt; Marc C Johnson
Journal:  Nat Struct Mol Biol       Date:  2004-06-20       Impact factor: 15.369

3.  Efficiency of human immunodeficiency virus type 1 postentry infection processes: evidence against disproportionate numbers of defective virions.

Authors:  James A Thomas; David E Ott; Robert J Gorelick
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

4.  Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies.

Authors:  Pascal Poignard; Maxime Moulard; Edwin Golez; Veronique Vivona; Michael Franti; Sara Venturini; Meng Wang; Paul W H I Parren; Dennis R Burton
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.

Authors:  Elena Chertova; Julian W Bess; Bruce J Crise; Raymond C Sowder II; Terra M Schaden; Joanne M Hilburn; James A Hoxie; Raoul E Benveniste; Jeffrey D Lifson; Louis E Henderson; Larry O Arthur
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  Influenza hemagglutinins outside of the contact zone are necessary for fusion pore expansion.

Authors:  Eugenia Leikina; Aditya Mittal; Myoung-Soon Cho; Kamran Melikov; Michael M Kozlov; Leonid V Chernomordik
Journal:  J Biol Chem       Date:  2004-04-12       Impact factor: 5.157

7.  Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions.

Authors:  Ping Zhu; Elena Chertova; Julian Bess; Jeffrey D Lifson; Larry O Arthur; Jun Liu; Kenneth A Taylor; Kenneth H Roux
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-10       Impact factor: 11.205

8.  The entry of entry inhibitors: a fusion of science and medicine.

Authors:  John P Moore; Robert W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

Review 9.  The HIV Env-mediated fusion reaction.

Authors:  Stephen A Gallo; Catherine M Finnegan; Mathias Viard; Yossef Raviv; Antony Dimitrov; Satinder S Rawat; Anu Puri; Stewart Durell; Robert Blumenthal
Journal:  Biochim Biophys Acta       Date:  2003-07-11

Review 10.  Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.

Authors:  Tom Matthews; Miklos Salgo; Michael Greenberg; Jain Chung; Ralph DeMasi; Dani Bolognesi
Journal:  Nat Rev Drug Discov       Date:  2004-03       Impact factor: 84.694

View more
  55 in total

1.  Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.

Authors:  Thomas J Ketas; Sophie Holuigue; Katie Matthews; John P Moore; Per Johan Klasse
Journal:  Virology       Date:  2011-10-22       Impact factor: 3.616

Review 2.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.

Authors:  Dennis R Burton; Lars Hangartner
Journal:  Annu Rev Immunol       Date:  2016-05-20       Impact factor: 28.527

3.  Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.

Authors:  Dennis R Burton; Ann J Hessell; Brandon F Keele; Per Johan Klasse; Thomas A Ketas; Brian Moldt; D Cameron Dunlop; Pascal Poignard; Lara A Doyle; Lisa Cavacini; Ronald S Veazey; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

Review 4.  Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

Authors:  Laura A VanBlargan; Leslie Goo; Theodore C Pierson
Journal:  Microbiol Mol Biol Rev       Date:  2016-10-26       Impact factor: 11.056

5.  Dense Array of Spikes on HIV-1 Virion Particles.

Authors:  Armando Stano; Daniel P Leaman; Arthur S Kim; Lei Zhang; Ludovic Autin; Jidnyasa Ingale; Syna K Gift; Jared Truong; Richard T Wyatt; Arthur J Olson; Michael B Zwick
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

6.  Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.

Authors:  Rajesh P Ringe; Pavel Pugach; Christopher A Cottrell; Celia C LaBranche; Gemma E Seabright; Thomas J Ketas; Gabriel Ozorowski; Sonu Kumar; Anna Schorcht; Marit J van Gils; Max Crispin; David C Montefiori; Ian A Wilson; Andrew B Ward; Rogier W Sanders; P J Klasse; John P Moore
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

7.  The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.

Authors:  Bimmi Shrestha; James D Brien; Soila Sukupolvi-Petty; S Kyle Austin; Melissa A Edeling; Taekyung Kim; Katie M O'Brien; Christopher A Nelson; Syd Johnson; Daved H Fremont; Michael S Diamond
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823

8.  Estimating the stoichiometry of HIV neutralization.

Authors:  Carsten Magnus; Roland R Regoes
Journal:  PLoS Comput Biol       Date:  2010-03-19       Impact factor: 4.475

9.  Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.

Authors:  Cleo G Anastassopoulou; Thomas J Ketas; Per Johan Klasse; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-16       Impact factor: 11.205

10.  Complementation of diverse HIV-1 Env defects through cooperative subunit interactions: a general property of the functional trimer.

Authors:  Karl Salzwedel; Edward A Berger
Journal:  Retrovirology       Date:  2009-08-11       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.